Adjuvant TACE to Reduce the HCC Recurrence After Resection

Inclusion Criteria: 1. Age 18\~75 years; 2. Eastern Cooperative Oncology Group performance status (ECOG PS) score \<=2; 3. Histologically confirmed hepatocellular carcinoma with microvessels invasion; 4. No previous treatment for HCC; 5. More than 5 cm solitary tumor before surgery confirmed by more than 2 radiological examinations; 6. R0 resection achieved; 7. No recurrence evidence in radiological follow-up 3\~7 weeks after surgery; 8. Adequate hematologic parameters and liver and kidney functions: (1) Neutrophils Absolute \>=1.5\*10\^9/L; (2) Hemoglobin \>=90g/L; (3) Platelet count \>=75\*10\^9/L; (4) Serum albumin \>=35g/L; (5) Serum total bilirubin \<=1.5\* upper limit of normal (ULN); (6) Serum Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \<2.5\*ULN; (7) Serum creatinine \<=1.5\*ULN; (8) International normalized ratio (INR) \<=1.5; 9. Give signed informed consent before enrollment. Exclusion Criteria: 1. Function impairment of vital organs (heart, lung, kidney, etc), serious infection or \>grade 2 adverse events (Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0); 2. Histologically confirmed of positive resection margin (R1 resection); 3. Previous or current malignant tumor beyond HCC; 4. Allergy to any agent of the TACE regimen; 5. History of organ transplantation; 6. Previously receiving other treatments for HCC; 7. Pregnant or breastfeeding women, and women of childbearing potential without adequate contraception; 8. Neurological or mental abnormalities that may affect cognitive assessment and inform consent; 9. Concomitant anti-tumor therapy or participating in other interventional clinical trials; 10. Other psychological, family or social reason, which would affect compliance with the study protocol.